Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRIA-IMT + pembrolizumab
- Development stage
- Unknown
- Lead developer
- BriaCell Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous (pembrolizumab), Intradermal Or Subcutaneous Injection (bria-imt Vaccine)
01
Overview
BRIA-IMT + pembrolizumab is a combination immunotherapy regimen used primarily for advanced or metastatic breast cancer. BRIA-IMT (also known as SV-BR-1-GM) is an allogeneic whole cell cancer vaccine designed to stimulate the immune system by presenting tumor antigens and "putting the foot on the gas" of immune activation. Pembrolizumab (brand name KEYTRUDA) is a monoclonal antibody that acts as an immune checkpoint inhibitor targeting PD-1, which "awakens" components of the immune system to enhance anti-tumor activity. The combination aims to produce additive or synergistic effects on tumor regression and disease stabilization, overcoming limitations such as HLA matching required by BRIA-IMT alone. Clinical data show favorable safety and promising efficacy in heavily pretreated metastatic breast cancer patients, including those with central nervous system metastases.
- Brand names
- KEYTRUDA
- Other names
- Bria-IMT + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BRIA-IMT + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRIA-IMT + pembrolizumab.